CompletedNot Applicable

Pharmacokinetics of High-dose Tigecycline in Critically Ill Patients

Poland37 participantsStarted 2017-01-15

Plain-language summary

The objective of this study is to describe the pharmacokinetics of tigecycline in critically ill patients receiving continuous venovenous haemodialysis (CVVHD) and to evaluate the frequency of pharmacokinetic/pharmacodynamic target attainment with high dosing strategy (200 mg loading dose and 100 mg/12h).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who require ICU treatment due to severe sepsis * age 18-80 years * CVVHD treatment * an eligible consent obtained from the patient or his/her attendant Exclusion Criteria: * allergy to tigecycline or meropenem * contraindication to CVVHD * lack of consent to participate in the study * age of patients below 18 or above 80 years

What they're measuring

Serum concentration of tigecycline

Timeframe: 72 hours for each patient from the tigecycline treatment initiation.

Trial details

NCT IDNCT03034174

SponsorMedical University of Lublin

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-12-15

View on ClinicalTrials.gov More Septic Shock trials